Safety and PK of Admilparant in Healthy Participants

Phase 1, randomised, double-blind trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Number of participants experiencing adverse events (AE), serious adverse events (SAE), death, or an AE leading to study discontinuation up to 30 days and Number of participants with potentially clinically significant changes in ECG parameters, vital signs, clinical laboratory parameters, or physical examinations up to 30 days. Started Feb 2018; status: completed.